HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma.
暂无分享,去创建一个
Robert Tibshirani | Ash A. Alizadeh | Ash A Alizadeh | Ronald Levy | R. Tibshirani | I. Lossos | Izidore S Lossos | Ranjani Rajapaksa | R. Rajapaksa | R. Levy
[1] Ash A. Alizadeh,et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. , 2002, Blood.
[2] P. Pavlidis,et al. Cutting Edge: STAT6 Serves as a Positive and Negative Regulator of Gene Expression in IL-4-Stimulated B Lymphocytes1 , 2002, The Journal of Immunology.
[3] R. Rees,et al. Th1/Th2 Cytokine Expression and its Relationship with Tumor Growth in B Cell Non-Hodgkin's Lymphoma (NHL) , 2002, Leukemia & lymphoma.
[4] Meland,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[5] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[6] Ulrich Siebenlist,et al. Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.
[7] R Tibshirani,et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. , 2001, Blood.
[8] Gouri Nanjangud,et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.
[9] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[10] J Diebold,et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. , 2000, Blood.
[11] Ash A. Alizadeh,et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[12] Y. Kumazawa,et al. Absence of interleukin-4 enhances germinal center reaction in secondary immune response. , 2000, Immunology letters.
[13] R. Tibshirani,et al. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. , 2000, Blood.
[14] I. Lossos,et al. Mutation analysis of the 5' noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma: evidence for recurrent mutations and intraclonal heterogeneity. , 2000, Blood.
[15] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[16] J Hermans,et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. , 1998, Blood.
[17] Klaus Rajewsky,et al. Somatic hypermutation in normal and transformed human B cells , 1998, Immunological reviews.
[18] Y. S. Choi,et al. The functional role of B cell antigen receptor stimulation and IL-4 in the generation of human memory B cells from germinal center B cells. , 1997, Journal of immunology.
[19] J C Reed,et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.
[20] B. Nathwani,et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .
[21] D C Linch,et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. , 1996, Blood.
[22] U. Storb,et al. The molecular basis of somatic hypermutation of immunoglobulin genes. , 1996, Current opinion in immunology.
[23] P. Gaulard,et al. Prognostic Significance of bcl-2 Protein Expression in Aggressive Non-Hodgkin's Lymphoma , 1996 .
[24] J Diebold,et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 1996, Blood.
[25] K. Offit,et al. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[26] J. Cambier,et al. Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM). , 1995, Journal of immunology.
[27] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[28] K. Rajewsky,et al. M17: a novel gene expressed in germinal centers. , 1994, International immunology.
[29] I. Maclennan. Germinal centers. , 1994, Annual review of immunology.
[30] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[31] T. Pawson,et al. SH2 domains recognize specific phosphopeptide sequences , 1993, Cell.
[32] J. Rossi,et al. Antiproliferative effects of interleukin-4 on freshly isolated non-Hodgkin malignant B-lymphoma cells. , 1992, Blood.
[33] Charles W. Taylor,et al. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms , 1990 .
[34] T. Grogan,et al. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. , 1990, Blood.
[35] B. Beutler,et al. Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[36] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .